With opioid abuse in the USA now a major crisis and the use of certain non-opioids in combination with these drugs a major potential risk, Thomas W Frederickson, lead author of the Society of Hospital Medicine guide Reducing Adverse Drug Events Related to Opioids (RADEO), writes about reducing the risk of death and the related US Food and Drug Administration (FDA) warnings in an Expert View piece.
It is described by some as ‘dead in bed’ syndrome. Respiratory arrest and death related to opioids has an incidence that is hard to measure, but the patient stories of near-misses sudden deaths following routine surgeries are real.
In a hospital setting, improper use of opioids can lead to dangerous sedation, respiratory depression, and death. The risks are compounded because opioids are the most prescribed class of medication in hospitals, leading it to be the second most common class of medication to cause adverse patient events. The good news is that, with the implementation of a rigorous quality improvement plan, patient harm from opioid-related respiratory depression can be preventable.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze